Marker Therapeutics
MRKR
74 hedge funds and large institutions have $56.9M invested in Marker Therapeutics in 2021 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 7 closing their positions.
200% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 7
179% more capital invested
Capital invested by funds: $20.4M → $56.9M (+$36.5M)
63% more call options, than puts
Call options by funds: $1.59M | Put options by funds: $971K
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
23% more funds holding
Funds holding: 60 → 74 (+14)
2.71% more ownership
Funds ownership: 29.33% → 32.03% (+2.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$13.1M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$4.14M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.65M |
| 4 |
ACM
Aisling Capital Management
New York
|
+$2.61M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$2.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$462K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$216K |
| 3 |
VF
Virtu Financial
New York
|
-$111K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$94.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$91.2K |
MRKR Hedge Fund Activity: Q1 2021 in Review
74 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q1 2021, worth a combined $56.9M — up 179% from $20.4M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MRKR positions and 7 closed out — a net gain of 14 holders — while 22 added to existing stakes and 16 trimmed.
The largest buyer was NEA Management Company, adding an estimated $13.1M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $462K sold.
- 74 institutional investors held Marker Therapeutics (MRKR) as of Q1 2021, up from 60 in Q4 2020.
- Funds reported $56.9M of Marker Therapeutics stock for Q1 2021, up 179% quarter-over-quarter.
- 21 funds opened new Marker Therapeutics positions in Q1 2021 and 7 closed out, a net change of +14 holders.
- The largest Marker Therapeutics buyer in Q1 2021 was NEA Management Company, an estimated $13.1M added.
- The largest Marker Therapeutics seller in Q1 2021 was Renaissance Technologies, an estimated $462K sold.
Based on aggregated 13F filings for Q1 2021.